drugset / Trial / NCT00381732

A Study to Evaluate the Efficacy and Safety of 2.5mg and 5mg Tadalafil Given Once a Day to Men With Erectile Dysfunction

NCT00381732

Phase 3 Completed 280 enrolled Eli Lilly and Company ICOS Corporation · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a multicenter, randomized, double blind, placebo-controlled, parallel design study to evaluate the efficacy and safety of 2.5mg and 5mg tadalafil taken once daily in men with erectile dysfunction.

Timeline

Start
2003-10
Primary completion
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tadalafil Small molecule 2.5 mg Oral
Comparator Tadalafil Small molecule 5 mg Oral

Indications